Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-05-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
第四届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the convening and decisions made at the ninth meeting of the fourth Supervisory Board, including approvals of changes to investment projects and establishment of a subsidiary. The document includes voting results and references to compliance with relevant laws and stock exchange rules. It is not a full financial report, audit report, or earnings release, nor is it a call transcript or management report. It is a formal announcement of board-level decisions, specifically from the Supervisory Board, which falls under Board/Management Information category.
2022-05-23 Chinese
关于变更超募资金投资建设年产1000吨核苷系列食品营养强化剂项目实施主体的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding a change in the implementation entity for a project funded by over-raised funds from a public stock issuance. It details the background of the fundraising, the use of funds, and the approval by the board, supervisory committee, independent directors, and the sponsoring institution. The document is relatively short (2239 characters) and focuses on a specific corporate action related to capital use and project implementation. It does not contain financial statements or detailed financial performance data. It is an announcement about a capital/financing update, specifically about the use and management of raised funds and changes in project implementation. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-05-23 Chinese
独立董事关于第四届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding specific board meeting matters, including changes to investment projects and asset purchases, and approval of establishing a subsidiary. It references compliance with stock exchange rules and company bylaws. The content is focused on governance and board decisions rather than financial results or report publication. The document length is short (1118 characters) and it is not a report itself but an opinion related to board matters. Therefore, it fits best under Board/Management Information (MANG).
2022-05-23 Chinese
关于新乡拓新药业股份有限公司变更部分募集资金投资项目实施地点、实施方式的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from a sponsoring institution (中天国富证券有限公司) regarding changes to the implementation location and method of certain fundraising investment projects by 新乡拓新药业股份有限公司. It references regulatory guidelines from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, discusses the use of proceeds from an IPO, and includes board, supervisory, and independent director approvals. The document is focused on the verification and compliance of changes to the use of raised funds, not the full financial report or earnings. It is not an announcement of a report publication but a formal verification opinion. This fits the definition of an Audit Report / Information (AR), which includes audit reports, applied accounting principles, and results of internal or regulatory reviews related to financial matters but is not a full annual or interim report. The document length is 3167 characters, which is relatively short but contains substantive content and formal opinions, not just a brief announcement or certification. Therefore, the best classification is AR with high confidence. Q2 2022
2022-05-23 Chinese
关于对外投资设立子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Xinxiang Tuoxin Pharmaceutical Co., Ltd. regarding its external investment to establish a subsidiary company. It details the investment amount, purpose, risks, and impact on the company, along with approvals from the board and independent directors. There is no financial data or report content, but rather a corporate announcement about a capital investment and subsidiary formation. This fits the category of Capital/Financing Update (CAP), as it concerns company fundraising and capital structure changes through establishing a new subsidiary.
2022-05-23 Chinese
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions from the 13th meeting of the 4th Board of Directors of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It details the convening of the board meeting, the agenda items discussed, voting results, and references to related announcements and opinions. The content focuses on board decisions such as changes in investment projects, establishment of subsidiaries, and calling a shareholders meeting. There is no financial data, audit information, or report publication mentioned. The document is clearly about board meeting resolutions and related governance matters, fitting the category of Board/Management Information (MANG). The document length is short (1691 characters), and it is not a report or announcement of a report publication, but a meeting resolution announcement.
2022-05-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.